Research
Hormonal
SGLT2 inhibitors and GLP-1 agonists provide significant cardiovascular and renal protection in Type 2 Diabetes, independent of their glucose-lowering effects.
If you have Type 2 Diabetes and are at risk for heart or kidney problems, ask your doctor about SGLT2 inhibitors or GLP-1 agonists. These medications have been shown to protect your heart and kidneys, offering benefits beyond just lowering blood sugar.
StrongSupportsHIGH confidence
The introduction of newer glucose-lowering agents, including sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 agonists, have brought about a paradigm shift in preventing the onset and progression of complications of type 2 diabetes, particularly cardiovascular and renal disease.
Why this rating
Based on multiple large RCTs (EMPA-REG, CANVAS, LEADER, etc.) and meta-analyses.
Source
Preventing diabetes complications
Sophie Templer et al. · Internal Medicine Journal · 2024
narrative_reviewCited 30×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →